– USA, NJ – Experic, a contract development and manufacturing organization and clinical supply services company, today announced the appointment of Derek Hennecke to its Board as an independent director.
About Derek Hennecke
Derek Hennecke currently serves on several boards, he’s a chairman of the board of Microsize and Particle Dynamics and board director of Grand River Aseptic Manufacturing, Inceptor Bio, Kineticos Disruptor Fund, and the Friedreich’s Ataxia Research Alliance. Previously, he was founder, president, and CEO of Xcelience, board director of Oragenics, vice-president and general manager of MDS Pharma Services, and held various leadership roles at DSM Biologics, DSM Anti-Infectives, and Gist-Brocades in the Netherlands, Mexico, and Egypt.
Mr. Hennecke received his Bachelor of Science in microbiology from the University of Alberta, Canada, and a Master’s in business administration from the Rotterdam School of Management at Erasmus University in the Netherlands. He is pursuing a Master of liberal arts in biology from Harvard University Extension School.
About Experic
Experic, a contract development and manufacturing organization, and pharmaceutical supply services company, supports every phase of a product’s life cycle from conception to clinical and commercial scale, across various dosing and packaging formats, including tablets, pellets, capsules, and low-dose dry powder inhalation. From our state-of-the-art, Class A cGMP facility, we manage global delivery of the highest quality products, even for expedited projects, while providing unparalleled knowledge, expertise, and customer service.
For more information: https://expericservices.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.